RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.'s open-market purchases and sales year by year since 2006, and every transaction reported to the SEC on Form 4: date, shares…
Insider buying and selling since 2016
RA CAPITAL MANAGEMENT, L.P. bought shares on the open market in 9 different years since 2016 across 21 companies. Sales in 3 of the 11 years since 2016.
RA CAPITAL MANAGEMENT, L.P. reported 49 open-market purchases and 34 sales since 2016; purchases in 9 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | 20×20 trades |
| 2025 | 18×18 trades | — |
| 2024 | 8×8 trades | — |
| 2023 | 6×6 trades | — |
| 2022 | 6×6 trades | — |
| 2021 | 4×4 trades | — |
| 2020 | 2×2 trades | 9×9 trades |
| 2019 | 1×1 trade | — |
| 2018 | 2×2 trades | — |
| 2017 | 2×2 trades | — |
| 2016 | — | 5×5 trades |
Insider at 21 companies
- Werewolf Therapeutics HOWL2025–2026 · 3 purchases, 20 sales
- Janux Therapeutics JANX2021–2025 · 7 purchases, 0 sales
- Tyra Biosciences TYRA2024–2025 · 7 purchases, 0 sales
- Mineralys Therapeutics MLYS2025 · 2 purchases, 0 sales
- Sionna Therapeutics SION2025 · 2 purchases, 0 sales
- Pepgen PEPG2025 · 1 purchase, 0 sales
- Ars Pharmaceuticals SPRY2023–2024 · 4 purchases, 0 sales
- Septerna SEPN2024 · 2 purchases, 0 sales
- Nkarta NKTX2024 · 1 purchase, 0 sales
- Fulcrum Therapeutics FULC2022–2023 · 4 purchases, 0 sales
- Wave Life Sciences WVE2017–2023 · 4 purchases, 0 sales
- Enliven Therapeutics ELVN2023 · 1 purchase, 0 sales
- Black Diamond Therapeutics BDTX2023 · 1 purchase, 0 sales
- Acumen Pharmaceuticals ABOS2023 · 1 purchase, 0 sales
- Cytek Biosciences CTKB2022 · 3 purchases, 0 sales
- Vor Biopharma VOR2021 · 2 purchases, 0 sales
- Rhythm Pharmaceuticals RYTM2020 · 0 purchases, 9 sales
- Phathom Pharmaceuticals PHAT2020 · 2 purchases, 0 sales
- Arvinas ARVN2018 · 1 purchase, 0 sales
- Kala Bio KALA2018 · 1 purchase, 0 sales
- Aclaris Therapeutics ACRS2016 · 0 purchases, 5 sales
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
Trades disclosed
Latest trade
Largest trade
Companies
Every disclosed trade
Every trade this person has disclosed
Newest first, each one linked to the filing it came from.
Already a member? Sign in
What this page holds
- Every disclosed trade, newest first
- How purchases did after they were reported
- Companies and committees involved
- A link to every official filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about RA CAPITAL MANAGEMENT, L.P.'s trades
Has RA CAPITAL MANAGEMENT, L.P. bought shares on the open market?
RA CAPITAL MANAGEMENT, L.P. bought shares on the open market in 9 different years since 2016 across 21 companies. Sales in 3 of the 11 years since 2016.
When did RA CAPITAL MANAGEMENT, L.P. last buy or sell shares?
In SEC filings since 2016: the latest open-market purchase is from 2025; the latest open-market sale is from 2026.
Which companies has RA CAPITAL MANAGEMENT, L.P. traded as an insider?
21 companies: Werewolf Therapeutics (HOWL, 2025–2026), Janux Therapeutics (JANX, 2021–2025), Tyra Biosciences (TYRA, 2024–2025), Mineralys Therapeutics (MLYS, 2025), Sionna Therapeutics (SION, 2025) and others.